Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 10,000 shares of the business’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $18.30, for a total value of $183,000.00. Following the sale, the director now owns 509,581 shares in the company, valued at approximately $9,325,332.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Entellus Medical Inc. (NASDAQ:ENTL) traded up 1.64% during midday trading on Friday, hitting $18.54. The company’s stock had a trading volume of 34,407 shares. The company’s market cap is $349.46 million. The stock has a 50 day moving average of $19.64 and a 200 day moving average of $18.49. Entellus Medical Inc. has a 52-week low of $13.72 and a 52-week high of $22.63.

Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings data on Thursday, November 3rd. The medical technology company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.13. Entellus Medical had a negative return on equity of 53.20% and a negative net margin of 36.91%. The business earned $17.90 million during the quarter, compared to analysts’ expectations of $17.93 million. During the same quarter last year, the business posted ($0.32) EPS. The company’s quarterly revenue was up 20.9% on a year-over-year basis. On average, equities analysts expect that Entellus Medical Inc. will post ($1.42) EPS for the current year.

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System increased its stake in shares of Entellus Medical by 0.6% in the third quarter. California State Teachers Retirement System now owns 15,817 shares of the medical technology company’s stock worth $351,000 after buying an additional 100 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Entellus Medical by 2.2% in the second quarter. Ameriprise Financial Inc. now owns 75,048 shares of the medical technology company’s stock worth $1,370,000 after buying an additional 1,612 shares during the period. Teachers Advisors Inc. increased its stake in shares of Entellus Medical by 21.7% in the second quarter. Teachers Advisors Inc. now owns 10,533 shares of the medical technology company’s stock worth $192,000 after buying an additional 1,876 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Entellus Medical by 2.7% in the third quarter. Northern Trust Corp now owns 96,534 shares of the medical technology company’s stock worth $2,141,000 after buying an additional 2,553 shares during the period. Institutional investors own 65.88% of the company’s stock.

A number of equities research analysts recently weighed in on ENTL shares. Zacks Investment Research upgraded Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Monday, August 8th. BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Entellus Medical in a research report on Friday, August 5th. Canaccord Genuity restated a “buy” rating and set a $23.00 price objective on shares of Entellus Medical in a research report on Friday, August 5th. Finally, Deutsche Bank AG restated a “buy” rating and set a $26.00 price objective (up previously from $25.00) on shares of Entellus Medical in a research report on Friday, November 4th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $22.75.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.